Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00163657 · ClinicalTrials.gov registry record · Phase 4
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
A Phase 4 study of Hepatitis C and End Stage Liver DIsease, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 312
- Enrollment target
- 1
- Study location
NCT00163657 is a Phase 4 study of Hepatitis C and End Stage Liver DIsease that has completed, run by Baylor Research Institute. The registered enrollment target is 312 participants, below the 1,887-participant average among 106 other Hepatitis C trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00163657, a Phase 4 study of Hepatitis C and End Stage Liver DIsease, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 312 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare three treatment regimens in patients who have received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C infection.
Conditions Studied
Interventions
- DRUG Tacrolimus
- DRUG Cyclosporine
- DRUG MMF
- DRUG Daclizumub
Study Locations (1)
Texas
- Baylor Regional Transplant Institute - Baylor University Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2002-07 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00163657
The ClinicalTrials.gov registry entry for NCT00163657 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,887-participant average among 106 other Hepatitis C trials with a reported enrollment target (83% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 4 interventions - of which Tacrolimus is the first listed.
NCT00163657 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00163657 about?
NCT00163657 is a clinical study titled "Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection". The purpose of this study is to compare three treatment regimens in patients who have received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C infection.
What is the current status of trial NCT00163657?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 312 participants. The study started on 2002-07. Estimated completion is 2007-01.
What conditions does trial NCT00163657 study?
This clinical trial studies the following conditions: Hepatitis C, End Stage Liver DIsease.
What interventions are being tested in trial NCT00163657?
The interventions under investigation include: Tacrolimus (DRUG), Cyclosporine (DRUG), MMF (DRUG), Daclizumub (DRUG).
Who is sponsoring clinical trial NCT00163657?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00163657 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
-
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.